Literature DB >> 7902065

Neural degeneration and the transport of neurotransmitters.

R H Edwards1.   

Abstract

A number of neurodegenerative diseases selectively affect distinct neuronal populations, but the mechanisms responsible for selective cell vulnerability have generally remained unclear. The toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reproduces the selective degeneration of dopaminergic neurons in the substantia nigra characteristic of Parkinson's disease. The plasma membrane dopamine transporter mediates this selective toxicity through accumulation of the active metabolite N-methyl-4-phenylpyridinium (MPP+). In contrast, the vesicular amine transporter protects against this form of injury by sequestering the toxin from its primary site of action in mitochondria. Together with the identification of defects in glutamate transport from patients with amyotrophic lateral sclerosis, these observations suggest that neurotransmitter transport may have a major role in neurodegenerative disease. The recent cloning of cDNAs encoding these transport proteins will help to explore this hypothesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902065     DOI: 10.1002/ana.410340504

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens.

Authors:  M J Nirenberg; J Chan; A Pohorille; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

2.  Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area.

Authors:  M J Nirenberg; J Chan; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

Review 3.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 4.  Molecular biology of glycinergic neurotransmission.

Authors:  F Zafra; C Aragón; C Giménez
Journal:  Mol Neurobiol       Date:  1997-06       Impact factor: 5.590

5.  The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei.

Authors:  M J Nirenberg; Y Liu; D Peter; R H Edwards; V M Pickel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

6.  Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.

Authors:  Kristin E Larsen; Edward A Fon; Teresa G Hastings; Robert H Edwards; David Sulzer
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 7.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

8.  Dopamine transporter genetic variants and pesticides in Parkinson's disease.

Authors:  Beate R Ritz; Angelika D Manthripragada; Sadie Costello; Sarah J Lincoln; Matthew J Farrer; Myles Cockburn; Jeff Bronstein
Journal:  Environ Health Perspect       Date:  2009-02-22       Impact factor: 9.031

Review 9.  Treatment of Parkinson's disease.

Authors:  M J Aminoff
Journal:  West J Med       Date:  1994-09

10.  Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons.

Authors:  Eugene V Mosharov; Kristin E Larsen; Ellen Kanter; Kester A Phillips; Krystal Wilson; Yvonne Schmitz; David E Krantz; Kazuto Kobayashi; Robert H Edwards; David Sulzer
Journal:  Neuron       Date:  2009-04-30       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.